Pharmanutra SpA (PHNU)

Currency in EUR
45.55
-0.25(-0.55%)
Closed·

PHNU Financial Summary

Key Ratios

P/E Ratio28.49
Price/Book7.6
Debt / Equity39.02%
Return on Equity28.39%
Dividend Yield2.18%
EBITDA30.24M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of EUR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.73%
Dividend Yield
2.18%
Industry Median 2.61%
Annualised payout
1.00
Paid annually
5-Years Growth
+16.80%
Growth Streak

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 79.00
(+73.44% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
0.25 / --
Revenue / Forecast
26.40M / --
EPS Revisions
Last 90 days

FAQ

What were Pharmanutra's earnings for the latest quarter?

The Pharmanutra EPS (TTM) is 1.73. Pharmanutra reported sales of 32.20, net income of 3.44, and EPS of 0.25 for the latest quarter.

What was Pharmanutra's net income for the latest quarter?

Pharmanutra's net income for the latest quarter was 3.44.

How did Pharmanutra's performance compare year-over-year in the latest quarter?

The company's revenue moved from 27.44 in the previous quarter to 32.20 in the latest quarter, and net income moved from 4.27 to 3.44 compared to the previous quarter.

What is Pharmanutra's net profit margin on a TTM basis?

Pharmanutra's trailing twelve months (TTM) net profit margin is 14.30%.

How does Pharmanutra's debt to equity ratio compare to industry standards?

Pharmanutra's total debt-to-equity ratio is 39.02%.

What is Pharmanutra's return on investment on a TTM basis?

Pharmanutra's trailing twelve months (TTM) return on investment (ROI) is 28.39%.

Did Pharmanutra gain or lose cash last quarter?

In the latest quarter, Pharmanutra's net change in cash was -2.20 million.

What were Pharmanutra's total assets and liabilities in the latest quarter?

As of the latest quarter, Pharmanutra reported total assets of 117.47 million and total liabilities of 27.34 million.

How has Pharmanutra's total revenue grown this year?

Pharmanutra's total revenue was 27.44 in the previous quarter and 32.20 in the latest quarter.

What is Pharmanutra's gross margin on a TTM basis?

Pharmanutra's trailing twelve months (TTM) gross margin is 51.00%.

What was Pharmanutra's revenue per share for the latest quarter?

Pharmanutra's revenue per share for the latest quarter was 40.32.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.